MY ACCOUNT | NEWSLETTER |

Anivive wins Best Animal Health Company by S&P Global


Anivive was named Best Animal Health Company of 2022 by S&P Global's Head of Animal Health for its annual North America award. Animal Health Connect by S&P Global, the most widely read publication reporting on the animal health industry, announced the award winners in late December 2022.

Anivive, a startup, joins a list of past recipients that include Zoetis, Merck and IDEXX, according to a news release

Joseph Harvey, head of animal health at S&P Global, said that Anivive showed the most significant growth and innovation in 2022. According to the news release, Harvey cited Anivive's discovery software, clinical trial platform and ability to successfully develop and monetize products across an array of unmet needs as reasons for bestowing the award.

Anivive highlights from 2022 include receiving conditional approval from the FDA for an oral tablet to treat canine lymphoma. The startup also published efficacy data for and established a final formulation an anti-fungal vaccine. In addition, Anivive received FDA acceptance and conditional approval for an antiviral to treat feline infectious peritonitis.

In terms of software validation, the company completed a successful rollout of its first clinical trial recruitment platform and also received commercial validation of its first drug repurposing platform to identify human therapeutics to treat pets. 

The Animal Health Awards are granted by a panel of industry expert judges to honor the achievements of companies who have had an outsized impact on the industry over the last 12 months.

Learn more about Anivive Lifesciences at https://www.anivive.com/

Like1
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Unlocking the potential of ICT innovation in veterinary healthcare: The pathway to improve practices and business model

Like0
Dislike0

Canine papillomavirus: status of diagnostic methods and vaccine innovations

Like0
Dislike0

Analysing innovations among cattle smallholders to evaluate the adequacy of breeding programs

Like0
Dislike0

40 Under 40: Dr. Cassi Fleming

Like0
Dislike0

CORRECTING and REPLACING Petwealth Emerges from Stealth with $1.7 Million in Funding, Landmark Partnerships, and a Mission to Become the Functional Health Platform for Pets

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top